Recombinant Human CDK3 Protein，His

CDK3 (Cyclin-Dependent Kinase 3) is a member of the cyclin-dependent kinase family, which plays a crucial role in the regulation of the cell cycle. Unlike other CDKs, CDK3 is primarily active during the G1 phase and is involved in the phosphorylation of target proteins that control cell cycle progression and differentiation. Its activity is tightly regulated by cyclins and various other cellular mechanisms, making it a key player in maintaining proper cell cycle regulation. Recent studies have indicated that CDK3 may have implications in several pathological conditions, including cancer, where dysregulation of cell cycle progression is a hallmark. Overexpression or altered regulation of CDK3 has been linked to malignant transformation, suggesting its potential as a therapeutic target in oncogenesis. Additionally, research has highlighted CDK3's role beyond cell proliferation, including involvement in cellular responses to stress and apoptosis. Given its significant functions, understanding the structural and functional characteristics of CDK3, including its protein interactions and regulatory mechanisms, is vital for elucidating its role in health and disease. Recombinant CDK3 proteins are being studied to explore their activity in various cellular contexts, helping to identify novel inhibitors or regulators that could serve as potential therapeutic agents in cancer treatment and other disorders associated with cell cycle dysregulation. This research aims to deepen our understanding of CDK3's functions and its potential as a drug target in oncology and regenerative medicine.